Screening for dysglycaemia in patients with coronary artery disease as reflected by fasting glucose, oral glucose tolerance test, and HbA1c: a report from EUROASPIRE IV-a survey from the European Society of Cardiology
File(s)EURHEARTJ-S-14-03059.pdf (4.2 MB)
Accepted version
Author(s)
Type
Journal Article
Abstract
Aims:
Three methods are used to identify dysglycaemia: fasting plasma glucose (FPG), 2-h post-load plasma glucose (2hPG) from the oral glucose tolerance test (OGTT), and glycated haemoglobin A1c (HbA1c). The aim was to describe the yield and concordance of FPG, HbA1c, and 2hPG alone, or in combination, to identify dysglycaemia in patients with coronary artery disease.
Methods and results:
In EUROASPIRE IV, a cross-sectional survey of patients aged 18–80 years with coronary artery disease in 24 European countries, 4004 patients with no reported history of diabetes had FPG, 2hPG, and HbA1c measured. All participants were divided into different glycaemic categories according to the ADA and WHO criteria for dysglycaemia. Using all screening tests together, 1158 (29%) had undetected diabetes. Out of them, the proportion identified by FPG was 75%, by 2hPG 40%, by HbA1c 17%, by FPG + HbA1c 81%, and by OGTT (=FPG + 2hPG) 96%. Only 7% were detected by all three methods FPG, 2hPG, and HbA1c. The ADA criteria (FPG + HbA1c) identified 90% of the population as having dysglycaemia compared with 73% with the WHO criteria (OGTT = FPG + 2hPG). Screening according to the ADA criteria for FPG + HbA1c identified 2643 (66%) as having a ‘high risk for diabetes’, while the WHO criteria for FPG + 2hPG identified 1829 patients (46%).
Conclusion:
In patients with established coronary artery disease, the OGTT identifies the largest number of patients with previously undiagnosed diabetes and should be the preferred test when assessing the glycaemic state of such patients.
Three methods are used to identify dysglycaemia: fasting plasma glucose (FPG), 2-h post-load plasma glucose (2hPG) from the oral glucose tolerance test (OGTT), and glycated haemoglobin A1c (HbA1c). The aim was to describe the yield and concordance of FPG, HbA1c, and 2hPG alone, or in combination, to identify dysglycaemia in patients with coronary artery disease.
Methods and results:
In EUROASPIRE IV, a cross-sectional survey of patients aged 18–80 years with coronary artery disease in 24 European countries, 4004 patients with no reported history of diabetes had FPG, 2hPG, and HbA1c measured. All participants were divided into different glycaemic categories according to the ADA and WHO criteria for dysglycaemia. Using all screening tests together, 1158 (29%) had undetected diabetes. Out of them, the proportion identified by FPG was 75%, by 2hPG 40%, by HbA1c 17%, by FPG + HbA1c 81%, and by OGTT (=FPG + 2hPG) 96%. Only 7% were detected by all three methods FPG, 2hPG, and HbA1c. The ADA criteria (FPG + HbA1c) identified 90% of the population as having dysglycaemia compared with 73% with the WHO criteria (OGTT = FPG + 2hPG). Screening according to the ADA criteria for FPG + HbA1c identified 2643 (66%) as having a ‘high risk for diabetes’, while the WHO criteria for FPG + 2hPG identified 1829 patients (46%).
Conclusion:
In patients with established coronary artery disease, the OGTT identifies the largest number of patients with previously undiagnosed diabetes and should be the preferred test when assessing the glycaemic state of such patients.
Date Issued
2015-02-10
Date Acceptance
2015-01-08
Citation
European Heart Journal, 2015, 36 (19), pp.1171-U98
ISSN
1522-9645
Publisher
Oxford University Press (OUP)
Start Page
1171
End Page
U98
Journal / Book Title
European Heart Journal
Volume
36
Issue
19
Copyright Statement
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2015. This is a pre-copy-editing, author-produced version of an article accepted for publication in the European Heart Journal following peer review. The definitive publisher-authenticated version is available online at: https://dx.doi.org/10.1093/eurheartj/ehv008.
Sponsor
Imperial College Healthcare NHS Trust - CLRN Funding
Imperial College Healthcare NHS Trust - CLRN Funding
Imperial College Healthcare NHS Trust
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000356185300015&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Grant Number
WHCP_P46405
RDLRN
RDLRN
Subjects
Science & Technology
Life Sciences & Biomedicine
Cardiac & Cardiovascular Systems
Cardiovascular System & Cardiology
Coronary artery disease
Diabetes
Impaired fasting glucose
Impaired glucose tolerance
HbA1c
Oral glucose tolerance test
ACUTE MYOCARDIAL-INFARCTION
DIABETES-MELLITUS
PLASMA-GLUCOSE
GLYCATED HEMOGLOBIN
HEART
A1C
MORTALITY
RISK
ATHEROSCLEROSIS
ABNORMALITIES
Publication Status
Published